Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

Wilms’ Tumour 1 (WT1) is a zinc finger transcription factor that is over-expressed in acute myeloid leukaemia (AML). Its restricted expression in normal tissues makes it a promising target for novel immunotherapies aiming to accentuate the cytotoxic T lymphocyte (CTL) response against AML. Here we r...

Descripción completa

Detalles Bibliográficos
Autores principales: Uttenthal, Benjamin, Martinez-Davila, Irma, Ivey, Adam, Craddock, Charles, Chen, Frederick, Virchis, Andras, Kottaridis, Panagiotis, Grimwade, David, Khwaja, Asim, Stauss, Hans, Morris, Emma C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253125/
https://www.ncbi.nlm.nih.gov/pubmed/24422723
http://dx.doi.org/10.1111/bjh.12637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253125/
https://www.ncbi.nlm.nih.gov/pubmed/24422723
http://dx.doi.org/10.1111/bjh.12637

Ejemplares similares